| Name | Procainamide |
| Description | Procainamide (Novocainamide) is a specific and potent DNA methyltransferase 1 (DNMT1) inhibitor and a Class 1A antiarrhythmic agent, with potential applications in cancer and arrhythmia research [1] [2]. |
| In vitro | HCT116, HCT116 DNMT1−/−, and HCT116 DNMT3b−/− cells were treated with PBS, pH 7.4 or 0.5 mM procainamide for 96 h. Procainamide treatment of HCT116 DNMT3b−/− cells decreased m5dC content by 11.5%, but treatment of HCT116 DNMT1−/− cells did not decrease m5dC content. These results suggested that DNMT1 was the intracellular target of procainamide[1]. |
| Storage | High Volatility
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (1062.34 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (4.25 mM), Sonication is recommended.
10% DMSO+90% Saline : 10 mg/mL (42.49 mM), Solution.
|
| Keywords | Procainamide | DNMT1 | DNAMethyltransferase | DNA Methyltransferase |
| Inhibitors Related | Carbamazepine | Uridine 5'-monophosphate disodium salt | Hydrochlorothiazide | 1,8-Cineole | Tetraethylammonium bromide | Tetraethylammonium chloride | Cesium chloride | Chenodeoxycholic acid | 4-Aminopyridine | 2,2,2-Trichloroethanol | Nifedipine | Indapamide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Approved Drug Library | Epigenetics Compound Library | Toxic Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bitter Compound library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
